Bristol Genetics Laboratory

North Bristol NHS Trust

Fluorescence *in situ* Hybridisation (FISH) in Non- Hodgkin Lymphoma (NHL)

Contact details
Bristol Genetics Laboratory
Pathology Sciences
Southmead Hospital
Bristol, BS10 5NB
Enquiries: 0117 414 6168
nbn-tr.geneticsenquiries@nhs.net

Head of department:
Eileen Roberts FRCPath

Consultant Lead for Oncology Genetics:
Chris Wragg FRCPath

Service Lead:
Abby Palmer
Abigail.Palmer@nbt.nhs.uk

Sample Requirements:
Bone marrow and peripheral blood samples in transport media or Lithium Heparin (only if >20% infiltration has been confirmed)

2-4 µm thick formalin fixed paraffin embedded tumour tissue sections mounted on APES or 'sticky' slides for each test required with an accompanying H&E slide with regions of tumour highlighted.

All samples should be labelled with patient name, date of birth and pathology block number.

Samples must be accompanied by a FULLY completed genetics request form including details of test, patient postcode, NHS number, referring clinician and unit/hospital (available as download at https://www.nbt.nhs.uk/severn-pathology/pathology-services/bristol-genetics-laboratory-bgl or from the laboratory).

Consent:
All genetic testing requires consent. It is the responsibility of the referring clinician to ensure that appropriate consent has been obtained.

Laboratory Contact
For enquiries/requesting contact Christopher.Wragg@nbt.nhs.uk or Abigail.Palmer@nbt.nhs.uk

Introduction

Non-Hodgkins Lymphoma (NHL) encompasses a collection of diseases, many of which are associated with specific gene rearrangements. Identification of the sub-types of NHL can have a profound effect on treatment plan and overall success. Fluorescence *in situ* hybridisation (FISH) is an important tool in classification of NHL subtypes, and can be applied to formalin fixed paraffin embedded sections.

Service offered

We offer a range of testing using CE marked probes in an accredited Genetics laboratory. Additional testing can be developed on request.

Disease	FISH Test
Mantle cell lymphoma (MCL)	IGH/CCND1
Follicular lymphoma (FL)	IGH/BCL2, BCL2, BCL6
Burkitt lymphoma	MYC
Diffuse large B-cell lymphoma (DLBCL)	BCL6, BCL2, MYC,
High-grade B-cell lymphomas, with and without MYC and BCL2 or BCL6 translocations	BCL6, BCL2, MYC,
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)	MALT1
ALK-positive large B-cell lymphoma	ALK
Anaplastic large cell lymphoma (ALCL)	ALK
ALK-negative anaplastic large cell lymphoma	IRF4/DUSP22
B-NHL	IGH
T-NHL	TRD



Target Reporting Time

FFPE samples 7-14 days

Blood and bone marrow referrals 5-10 days

Please contact the laboratory for up to date prices

Quality

The laboratory participates in UK NEQAS schemes

Reference

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC Press; 2008.
2. Swerdlow SH, Campo E, Pileri S et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. BLOOD 2016; 127(20);2375-2390

Information document No.82 Version 3
Active date of this version: 12/07/2016
DETAILS CORRECT AT DATE OF PRINTING ONLY.
Approved by: Christopher Wragg

Exceptional healthcare, personally delivered

CPA
Accredited Medical Laboratory
Reference No: 2907